Evaluation of health surveillance system attributes: the case of neglected tropical diseases in Kenya

Control of preventive chemotherapy-targeted neglected tropical diseases (PC-NTDs) depends on strengthened health techniques. Efficient health data techniques present an impetus to reaching the sustainable growth aim geared toward ending PC-NTD epidemics. However, there’s restricted evaluation of surveillance system capabilities linked to PC-NTDs and hinged on optimum efficiency of surveillance system attributes. The examine aimed to guage surveillance system attributes based mostly on healthcare staff’ perceptions in relation to PC-NTDs endemic in Kenya. A cross-sectional health facility survey was used to purposively pattern respondents concerned in illness surveillance actions.
Consenting respondents accomplished a self-administered questionnaire that assessed their perceptions on surveillance system attributes on a five-point likert scale. Frequency distributions for every level in the likert scale had been analysed to find out health staff’ general perceptions. Data was analysed utilizing descriptive statistics and estimated median values with corresponding interquartile ranges used to summarise reporting charges. Factor evaluation recognized variables measuring particular latent attributes. Pearson’s chi-square and Fisher’s precise checks examined associations between categorical variables. Thematic evaluation was carried out for questionnaire open-ended responses.
  Most (88%) respondents labored in public health amenities with 71% stationed in second-tier amenities. Regarding PC-NTDs, respondents perceived the surveillance system to be easy (55%), acceptable (50%), secure (41%), versatile (41%), helpful (51%) and to supply high quality knowledge (25%). Facility locality, facility sort, respondents’ schooling stage and years of work expertise had been related to perceived opinion on acceptability and stability respectively. Median month-to-month reporting timeliness and completeness charges for amenities had been 75 (58.3, 83.3) and 83.Three respectively.
Higher-level amenities met reporting timeliness (p < 0.001) and completeness (p < 0.001) thresholds in comparison with lower-level amenities.  Health personnel had decrease perceptions on the stability, flexibility and knowledge high quality of the surveillance system contemplating PC-NTDs. Reporting timeliness and completeness charges decreased in 2017 in comparison with earlier surveillance intervals. Strengthening all surveillance capabilities would affect health staff’ perceptions and enhance surveillance system general efficiency with regard to PC-NTDs.

An Overview of Current Uses and Future Opportunities for Computer-Assisted Design of Vaccines for Neglected Tropical Diseases

Neglected tropical diseases are infectious diseases that impose excessive morbidity and mortality charges over 1.5 billion individuals worldwide. Originally restricted to tropical and subtropical areas, altering local weather circumstances have elevated their potential to emerge elsewhere. Control of their impression suffers from shortages like poor epidemiological surveillance or irregular drug distribution, and a few NTDs nonetheless lack of acceptable diagnostics and/or environment friendly therapeutics. For these, availability of vaccines to forestall new infections, or the worsening of these already established, would imply a significant breakthrough.

However, solely dengue and rabies rely with permitted vaccines at current. Herein, we evaluate the state-of-the-art of vaccination methods for NTDs, setting the deal with third technology vaccines and the idea of reverse vaccinology. Its functionality to handle pathogens´ organic complexity, seemingly contributing to save lots of developmental prices is mentioned. The use of computational instruments is a elementary assist to research more and more massive datasets geared toward designing vaccine candidates with the highest, probably, alternatives to succeed. Ultimately, we determine and analyze these research that took an in silico method to search out vaccine candidates, and experimentally assessed their immunogenicity and/or safety capabilities.

Neglected tropical diseases (NTDs) are a various group of communicable diseases that principally impression the world’s poorest individuals. The use of digital health applied sciences is an rising and promising manner to enhance illness prevention, prognosis, case detection, therapy supply, and affected person follow-up and facilitating health facility appointments thereby bettering health outcomes. While the rising implementation of digital health applied sciences is clear, there’s a lack of complete proof on the impression of digital health applied sciences in the management of NTDs. The important goal of this evaluate was to map totally different items of proof on the use of digital health applied sciences for case detection, administration, and therapy end result of the neglected tropical illness.

Evaluation of health surveillance system attributes: the case of neglected tropical diseases in Kenya

Rethinking neglected tropical illness prevalence survey design and evaluation: a geospatial paradigm

Current strategies for the design and evaluation of neglected tropical illness prevalence surveys largely depend on classical survey sampling concepts that deal with prevalence knowledge from totally different places as an impartial random pattern from the chance distribution induced by a random sampling design. We set out an alternate, explicitly geospatial paradigm that may ship far more exact estimates of the geospatial variation in prevalence over a rustic or area of curiosity. We describe the benefits of this method below three headings: streamlining, whereby extra exact outcomes may be obtained with smaller pattern sizes; integrating, whereby a joint evaluation of knowledge from two or extra diseases can convey additional positive aspects in precision; and adapting, whereby the selection of future sampling location is knowledgeable by previous knowledge.

AZI2 Antibody

ABF0553 100 ug
EUR 438

AZI2 antibody

70R-32139 100 ug
EUR 327
Description: Rabbit polyclonal AZI2 antibody

AZI2 Antibody

ABD3437 100 ug
EUR 438

AZI2 Antibody

34065-100ul 100ul
EUR 252

AZI2 Antibody

34065-50ul 50ul
EUR 187

AZI2 Antibody

DF3437 200ul
EUR 304
Description: AZI2 Antibody detects endogenous levels of total AZI2.

AZI2 Antibody

1-CSB-PA003368
  • EUR 222.00
  • EUR 195.00
  • 100ug
  • 50ug
  • Form: Liquid
  • Buffer: Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Description: A polyclonal antibody against AZI2. Recognizes AZI2 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: WB, IHC, IF, ELISA;WB:1/500-1/2000.IHC:1/100-1/300.IF:1/200-1/1000.ELISA:1/20000

AZI2 Antibody

CSB-PA596738-
EUR 335
  • Form: liquid
  • Buffer: Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific
  • Show more
Description: A polyclonal antibody against AZI2. Recognizes AZI2 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB;WB:1:500-1:3000

AZI2 Antibody

CSB-PA596738-100ul 100ul
EUR 316
  • Form: liquid
  • Buffer: Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific
  • Show more
Description: A polyclonal antibody against AZI2. Recognizes AZI2 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB;WB:1:500-1:3000

AZI2 Antibody

1-CSB-PA863992LA01HU
  • EUR 317.00
  • EUR 335.00
  • 100ug
  • 50ug
  • Form: Liquid
  • Buffer: Preservative: 0.03% Proclin 300
    Constituents: 50% Glycerol, 0.01M PBS, pH 7.4 >95%, Protein G purified
Description: A polyclonal antibody against AZI2. Recognizes AZI2 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC, IF; Recommended dilution: IHC:1:20-1:200, IF:1:50-1:200

Azi2/ Rat Azi2 ELISA Kit

ELI-33379r 96 Tests
EUR 886

AZI2 Conjugated Antibody

C34065 100ul
EUR 397

anti- AZI2 antibody

FNab00758 100µg
EUR 505.25
  • Recommended dilution: WB: 1:500-1:2000
  • IHC: 1:20-1:200
  • Immunogen: 5-azacytidine induced 2
  • Uniprot ID: Q9H6S1
  • Gene ID: 64343
  • Research Area: Developmental biology
Description: Antibody raised against AZI2

Anti-AZI2 Antibody

A08235 100ul
EUR 397
Description: Rabbit Polyclonal AZI2 Antibody. Validated in WB and tested in Human, Mouse, Rat.

Anti-AZI2 antibody

PAab00758 100 ug
EUR 355

AZI2 siRNA

20-abx900565
  • EUR 551.00
  • EUR 732.00
  • 15 nmol
  • 30 nmol
  • Shipped within 5-10 working days.

AZI2 siRNA

20-abx908745
  • EUR 551.00
  • EUR 732.00
  • 15 nmol
  • 30 nmol
  • Shipped within 5-10 working days.

AZI2 siRNA

20-abx908746
  • EUR 551.00
  • EUR 732.00
  • 15 nmol
  • 30 nmol
  • Shipped within 5-10 working days.

AZI2 Antibody, HRP conjugated

1-CSB-PA863992LB01HU
  • EUR 317.00
  • EUR 335.00
  • 100ug
  • 50ug
  • Form: Liquid
  • Buffer: Preservative: 0.03% Proclin 300
    Constituents: 50% Glycerol, 0.01M PBS, pH 7.4 >95%, Protein G purified
Description: A polyclonal antibody against AZI2. Recognizes AZI2 from Human. This antibody is HRP conjugated. Tested in the following application: ELISA

AZI2 Antibody, FITC conjugated

1-CSB-PA863992LC01HU
  • EUR 317.00
  • EUR 335.00
  • 100ug
  • 50ug
  • Form: Liquid
  • Buffer: Preservative: 0.03% Proclin 300
    Constituents: 50% Glycerol, 0.01M PBS, pH 7.4 >95%, Protein G purified
Description: A polyclonal antibody against AZI2. Recognizes AZI2 from Human. This antibody is FITC conjugated. Tested in the following application: ELISA

AZI2 Antibody, Biotin conjugated

1-CSB-PA863992LD01HU
  • EUR 317.00
  • EUR 335.00
  • 100ug
  • 50ug
  • Form: Liquid
  • Buffer: Preservative: 0.03% Proclin 300
    Constituents: 50% Glycerol, 0.01M PBS, pH 7.4 >95%, Protein G purified
Description: A polyclonal antibody against AZI2. Recognizes AZI2 from Human. This antibody is Biotin conjugated. Tested in the following application: ELISA

AZI2 Blocking Peptide

AF0553-BP 1mg
EUR 195

AZI2 Blocking Peptide

DF3437-BP 1mg
EUR 195

Mouse AZI2 shRNA Plasmid

20-abx973842
  • EUR 801.00
  • EUR 1121.00
  • 150 µg
  • 300 µg
  • Shipped within 15-20 working days.

Rat AZI2 shRNA Plasmid

20-abx989925
  • EUR 801.00
  • EUR 1121.00
  • 150 µg
  • 300 µg
  • Shipped within 15-20 working days.

AZI2 ELISA KIT|Human

EF008030 96 Tests
EUR 689

Human AZI2 shRNA Plasmid

20-abx961990
  • EUR 801.00
  • EUR 1121.00
  • 150 µg
  • 300 µg
  • Shipped within 15-20 working days.

AZI2 Recombinant Protein (Human)

RP048181 100 ug Ask for price

AZI2 Recombinant Protein (Rat)

RP191693 100 ug Ask for price

AZI2 Recombinant Protein (Mouse)

RP118415 100 ug Ask for price

AZI2 Recombinant Protein (Mouse)

RP118418 100 ug Ask for price

5-Azacytidine-Induced Protein 2 (AZI2) Antibody

20-abx013797
  • EUR 314.00
  • EUR 98.00
  • EUR 398.00
  • EUR 495.00
  • 100 ug
  • 10 ug
  • 200 ug
  • 300 µg
  • Shipped within 5-10 working days.

5-Azacytidine-Induced Protein 2 (AZI2) Antibody

20-abx329457
  • EUR 314.00
  • EUR 244.00
  • 100 ug
  • 50 ug
  • Shipped within 5-10 working days.

5-Azacytidine-Induced Protein 2 (AZI2) Antibody

abx332767-100ul 100 ul
EUR 425
  • Shipped within 5-10 working days.

5-Azacytidine-Induced Protein 2 (AZI2) Antibody

20-abx333820
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug
  • Shipped within 5-10 working days.

5-Azacytidine-Induced Protein 2 (AZI2) Antibody

abx230758-100ug 100 ug
EUR 481
  • Shipped within 5-12 working days.

Azi2 ORF Vector (Mouse) (pORF)

ORF039473 1.0 ug DNA
EUR 506

Azi2 ORF Vector (Mouse) (pORF)

ORF039474 1.0 ug DNA
EUR 506

AZI2 ORF Vector (Human) (pORF)

ORF016061 1.0 ug DNA Ask for price

Azi2 ORF Vector (Rat) (pORF)

ORF063899 1.0 ug DNA
EUR 506

AZI2 ELISA Kit (Human) (OKEH07990)

OKEH07990 96 Wells
EUR 896
Description: Description of target: AZI2, or NAP1, contributes to the activation of NFKB (see MIM 164011)-dependent gene expression by activating IKK-related kinases, such as NAK (TBK1; MIM 604834) (Fujita et al., 2003 [PubMed 14560022]).[supplied by OMIM, Mar 2008];Species reactivity: Human;Application: ELISA;Assay info: Assay Methodology: Quantitative Sandwich ELISA;Sensitivity: 0.093ng/mL

5-Azacytidine-Induced Protein 2 (AZI2) Antibody (HRP)

20-abx334503
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug
  • Shipped within 5-10 working days.

5-Azacytidine-Induced Protein 2 (AZI2) Antibody (FITC)

20-abx334504
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug
  • Shipped within 5-10 working days.

5-Azacytidine-Induced Protein 2 (AZI2) Antibody (Biotin)

20-abx334505
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug
  • Shipped within 5-10 working days.

AZI2 sgRNA CRISPR Lentivector set (Human)

K0162101 3 x 1.0 ug
EUR 339

Azi2 sgRNA CRISPR Lentivector set (Mouse)

K3190301 3 x 1.0 ug
EUR 339

Azi2 sgRNA CRISPR Lentivector set (Rat)

K7135801 3 x 1.0 ug
EUR 339

AZI2 sgRNA CRISPR Lentivector (Human) (Target 1)

K0162102 1.0 ug DNA
EUR 154

AZI2 sgRNA CRISPR Lentivector (Human) (Target 2)

K0162103 1.0 ug DNA
EUR 154

AZI2 sgRNA CRISPR Lentivector (Human) (Target 3)

K0162104 1.0 ug DNA
EUR 154

Azi2 sgRNA CRISPR Lentivector (Mouse) (Target 1)

K3190302 1.0 ug DNA
EUR 154

Azi2 sgRNA CRISPR Lentivector (Mouse) (Target 2)

K3190303 1.0 ug DNA
EUR 154

Azi2 sgRNA CRISPR Lentivector (Mouse) (Target 3)

K3190304 1.0 ug DNA
EUR 154

Azi2 sgRNA CRISPR Lentivector (Rat) (Target 1)

K7135802 1.0 ug DNA
EUR 154

Azi2 sgRNA CRISPR Lentivector (Rat) (Target 2)

K7135803 1.0 ug DNA
EUR 154

Azi2 sgRNA CRISPR Lentivector (Rat) (Target 3)

K7135804 1.0 ug DNA
EUR 154

AZI2 Protein Vector (Human) (pPB-C-His)

PV064241 500 ng Ask for price

AZI2 Protein Vector (Human) (pPB-N-His)

PV064242 500 ng Ask for price

AZI2 Protein Vector (Human) (pPM-C-HA)

PV064243 500 ng Ask for price

AZI2 Protein Vector (Human) (pPM-C-His)

PV064244 500 ng Ask for price

AZI2 Protein Vector (Human) (pPB-His-MBP)

PV325866 500 ng Ask for price

AZI2 Protein Vector (Human) (pPB-His-GST)

PV325867 500 ng Ask for price

AZI2 Protein Vector (Rat) (pPB-C-His)

PV255594 500 ng
EUR 603

AZI2 Protein Vector (Rat) (pPB-N-His)

PV255595 500 ng
EUR 603

AZI2 Protein Vector (Rat) (pPM-C-HA)

PV255596 500 ng
EUR 603

AZI2 Protein Vector (Rat) (pPM-C-His)

PV255597 500 ng
EUR 603

AZI2 Protein Vector (Mouse) (pPB-C-His)

PV157890 500 ng
EUR 603

AZI2 Protein Vector (Mouse) (pPB-N-His)

PV157891 500 ng
EUR 603

AZI2 Protein Vector (Mouse) (pPM-C-HA)

PV157892 500 ng
EUR 603

AZI2 Protein Vector (Mouse) (pPM-C-His)

PV157893 500 ng
EUR 603

AZI2 Protein Vector (Mouse) (pPB-C-His)

PV157894 500 ng
EUR 603

AZI2 Protein Vector (Mouse) (pPB-N-His)

PV157895 500 ng
EUR 603

AZI2 Protein Vector (Mouse) (pPM-C-HA)

PV157896 500 ng
EUR 603

AZI2 Protein Vector (Mouse) (pPM-C-His)

PV157897 500 ng
EUR 603

Azi2 3'UTR Luciferase Stable Cell Line

TU201164 1.0 ml Ask for price

Azi2 3'UTR GFP Stable Cell Line

TU152443 1.0 ml Ask for price

AZI2 3'UTR Luciferase Stable Cell Line

TU001559 1.0 ml
EUR 1521

Azi2 3'UTR Luciferase Stable Cell Line

TU102443 1.0 ml Ask for price

AZI2 3'UTR GFP Stable Cell Line

TU051559 1.0 ml
EUR 1521

Azi2 3'UTR GFP Stable Cell Line

TU251164 1.0 ml Ask for price

AZI2 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV)

LV652339 1.0 ug DNA
EUR 682

AZI2 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC)

LV652343 1.0 ug DNA
EUR 682

AZI2 Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a)

LV652344 1.0 ug DNA
EUR 682

Bovine 5- azacytidine- induced protein 2, AZI2 ELISA KIT

ELI-34726b 96 Tests
EUR 928

Human 5- azacytidine- induced protein 2, AZI2 ELISA KIT

ELI-49615h 96 Tests
EUR 824

Mouse 5- azacytidine- induced protein 2, Azi2 ELISA KIT

ELI-50028m 96 Tests
EUR 865

Human 5-Azacytidine-Induced Protein 2 (AZI2) ELISA Kit

abx385978-96tests 96 tests
EUR 754
  • Shipped within 20 working days.

AZI2 Protein Vector (Human) (pPM-N-D-C-HA)

PV325868 500 ng Ask for price

AZI2 Protein Vector (Human) (pPM-N-D-C-His)

PV325869 500 ng Ask for price

AZI2 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human)

K0162105 3 x 1.0 ug
EUR 376

Azi2 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Mouse)

K3190305 3 x 1.0 ug
EUR 376

Azi2 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Rat)

K7135805 3 x 1.0 ug
EUR 376

AZI2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 1)

K0162106 1.0 ug DNA
EUR 167

AZI2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 2)

K0162107 1.0 ug DNA
EUR 167

AZI2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 3)

K0162108 1.0 ug DNA
EUR 167

Azi2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 1)

K3190306 1.0 ug DNA
EUR 167

Azi2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 2)

K3190307 1.0 ug DNA
EUR 167

Azi2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 3)

K3190308 1.0 ug DNA
EUR 167

AZI2 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-C-term-HA)

LV652340 1.0 ug DNA
EUR 682

AZI2 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro)

LV652341 1.0 ug DNA
EUR 740

AZI2 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro)

LV652342 1.0 ug DNA
EUR 740

Azi2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 1)

K7135806 1.0 ug DNA
EUR 167

Azi2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 2)

K7135807 1.0 ug DNA
EUR 167

Azi2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 3)

K7135808 1.0 ug DNA
EUR 167

H2B Antibody Antibody

AF4659 200ul
EUR 376
Description: H2B Antibody Antibody detects endogenous levels of H2B.

CD11b Antibody Antibody

ABD2911 100 ug
EUR 438

anti- Antibody^Polyclonal antibody control antibody

LSMab09882 100 ug
EUR 438

Ly1 Antibody Reactive (LYAR) Antibody

20-abx123734
  • EUR 411.00
  • EUR 592.00
  • 100 ul
  • 200 ul
  • Shipped within 5-10 working days.

Anti-Glycolipid Antibody (AGA) Antibody

abx036399-100ug 100 ug
EUR 391
  • Shipped within 5-10 working days.

Ly1 Antibody Reactive (LYAR) Antibody

abx033330-400ul 400 ul
EUR 523
  • Shipped within 5-10 working days.

Ly1 Antibody Reactive (LYAR) Antibody

abx033330-80l 80 µl
EUR 286
  • Shipped within 5-10 working days.

Ly1 Antibody Reactive (LYAR) Antibody

20-abx008109
  • EUR 300.00
  • EUR 439.00
  • EUR 189.00
  • 100 ul
  • 200 ul
  • 30 ul
  • Shipped within 5-10 working days.

Anti-Glycolipid Antibody (AGA) Antibody

20-abx004855
  • EUR 411.00
  • EUR 592.00
  • EUR 182.00
  • EUR 314.00
  • 100 ul
  • 200 ul
  • 20 ul
  • 50 ul
  • Shipped within 5-10 working days.

Ly1 Antibody Reactive (LYAR) Antibody

20-abx014333
  • EUR 314.00
  • EUR 98.00
  • EUR 398.00
  • EUR 495.00
  • 100 ug
  • 10 ug
  • 200 ug
  • 300 µg
  • Shipped within 5-10 working days.

Ly1 Antibody Reactive (LYAR) Antibody

20-abx324434
  • EUR 314.00
  • EUR 244.00
  • 100 ug
  • 50 ug
  • Shipped within 5-10 working days.

Anti-Glycoprotein Antibody (GP) Antibody

20-abx319900
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug
  • Shipped within 5-10 working days.

Anti-Glycoprotein Antibody (GP) Antibody

20-abx319901
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug
  • Shipped within 5-10 working days.

Anti-Glycoprotein Antibody (GP) Antibody

20-abx319905
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug
  • Shipped within 5-10 working days.

Anti-Glycoprotein Antibody (GP) Antibody

20-abx319913
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug
  • Shipped within 5-10 working days.

Ly1 Antibody Reactive (LYAR) Antibody

20-abx311665
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug
  • Shipped within 5-10 working days.

Ly1 Antibody Reactive (LYAR) Antibody

abx234901-100ug 100 ug
EUR 551
  • Shipped within 5-12 working days.

Anti-Glycolipid Antibody (AGA) Antibody

abx230204-100ug 100 ug
EUR 481
  • Shipped within 5-12 working days.

Anti-Anti-SEPT2 Antibody antibody

STJ28365 100 µl
EUR 277

Anti-Anti-SEPT7 Antibody antibody

STJ28963 100 µl
EUR 277
Description: This gene encodes a protein that is highly similar to the CDC10 protein of Saccharomyces cerevisiae. The protein also shares similarity with Diff 6 of Drosophila and with H5 of mouse. Each of these similar proteins, including the yeast CDC10, contains a GTP-binding motif. The yeast CDC10 protein is a structural component of the 10 nm filament which lies inside the cytoplasmic membrane and is essential for cytokinesis. This human protein functions in gliomagenesis and in the suppression of glioma cell growth, and it is required for the association of centromere-associated protein E with the kinetochore. Alternative splicing results in multiple transcript variants. Several related pseudogenes have been identified on chromosomes 5, 7, 9, 10, 11, 14, 17 and 19.

Anti-Anti-SEPT6 antibody antibody

STJ11100949 100 µl
EUR 277
Description: This gene is a member of the septin family of GTPases. Members of this family are required for cytokinesis. One version of pediatric acute myeloid leukemia is the result of a reciprocal translocation between chromosomes 11 and X, with the breakpoint associated with the genes encoding the mixed-lineage leukemia and septin 2 proteins. This gene encodes four transcript variants encoding three distinct isoforms. An additional transcript variant has been identified, but its biological validity has not been determined.

Anti-Anti-SEPT2 Antibody antibody

STJ25475 100 µl
EUR 277

Anti-Anti-SEPT5 Antibody antibody

STJ25477 100 µl
EUR 277
Description: This gene is a member of the septin gene family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. This gene is mapped to 22q11, the region frequently deleted in DiGeorge and velocardiofacial syndromes. A translocation involving the MLL gene and this gene has also been reported in patients with acute myeloid leukemia. Alternative splicing results in multiple transcript variants. The presence of a non-consensus polyA signal (AACAAT) in this gene also results in read-through transcription into the downstream neighboring gene (GP1BB; platelet glycoprotein Ib), whereby larger, non-coding transcripts are produced.

Anti-Anti-SEPT8 Antibody antibody

STJ25479 100 µl
EUR 277
Description: This gene is a member of the septin family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse, and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. Multiple alternatively spliced transcript variants encoding different isoforms have been found for this gene.

Anti-Anti-SEPT9 Antibody antibody

STJ111369 100 µl
EUR 277
Description: This gene is a member of the septin family involved in cytokinesis and cell cycle control. This gene is a candidate for the ovarian tumor suppressor gene. Mutations in this gene cause hereditary neuralgic amyotrophy, also known as neuritis with brachial predilection. A chromosomal translocation involving this gene on chromosome 17 and the MLL gene on chromosome 11 results in acute myelomonocytic leukemia. Multiple alternatively spliced transcript variants encoding different isoforms have been described.

Anti-Anti-SEPT11 Antibody antibody

STJ111530 100 µl
EUR 277

Anti-Anti-SEPT4 Antibody antibody

STJ112276 100 µl
EUR 277
Description: This gene is a member of the septin family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse, and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. This gene is highly expressed in brain and heart. Alternatively spliced transcript variants encoding different isoforms have been described for this gene. One of the isoforms (known as ARTS) is distinct; it is localized to the mitochondria, and has a role in apoptosis and cancer.

Anti-Anti-MARCH9 Antibody antibody

STJ112609 100 µl
EUR 277

Anti-Anti-SEPT11 Antibody antibody

STJ113941 100 µl
EUR 277

Anti-Anti-SEPT11 Antibody antibody

STJ114081 100 µl
EUR 277

Anti-Anti-SEPT5 Antibody antibody

STJ114819 100 µl
EUR 277
Description: This gene is a member of the septin gene family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. This gene is mapped to 22q11, the region frequently deleted in DiGeorge and velocardiofacial syndromes. A translocation involving the MLL gene and this gene has also been reported in patients with acute myeloid leukemia. Alternative splicing results in multiple transcript variants. The presence of a non-consensus polyA signal (AACAAT) in this gene also results in read-through transcription into the downstream neighboring gene (GP1BB; platelet glycoprotein Ib), whereby larger, non-coding transcripts are produced.

Anti-Anti-MARCH8 Antibody antibody

STJ114828 100 µl
EUR 277

Anti-Anti-MARCH6 Antibody antibody

STJ118549 100 µl
EUR 277
A complete of 996 probably related research had been generated from the preliminary search, and 6 research had been discovered to fulfill all the inclusion standards and included in the last evaluate. The evaluate discovered that telehealth, eHealth, mHealth, telemedicine, and digital health file had been used digital health applied sciences to evaluate their impression on case detection, illness administration, and therapy end result of neglected tropical diseases. Mobile health was a possible digital health know-how for lymphatic filariasis affected person identification and mHealth, eHealth, and digital health information discovered to enhance the service entry, outcomes, and monitoring of visceral leishmaniasis at the neighborhood health system.